BBC - (Virtus LifeSci Biotech Clinical Trials ETF)

 BBCのチャート


 BBCの企業情報

symbol BBC
会社名
分野(sector)   
産業(industry)   
業種   
概要 事業概要 --     
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/bbc
adr_tso
EBITDA EBITDA ー
終値(lastsale) 30.98
時価総額(marketcap) 30980123.92
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 BBCのテクニカル分析


 BBCのニュース

   There's A Really Good Chance You Missed One Of The Year's Best ETFs  2019/12/09 12:25:13 Benzinga
Investors have been piling into exchange traded funds again this year, mostly pure beta, core equity and fixed income funds. The list of the top asset-gathering ETFs reads like rundown of the usual suspects . There's nothing wrong with that, but as investors flock to broad market equity and aggregate bond funds to keep up with the Joneses, they miss out on tactical opportunities like the Virtus LifeSci Biotech Clinical Trials ETF (NYSE: BBC ). BBC, which turns five years old this week, is up 41.14% year to date, thanks in large part to a fourth-quarter gain of 25.7%. Why It's Important BBC tracks the LifeSci Biotechnology Clinical Trials Index, a basket of early-stage biotechnology companies. Said another way, BBC is chock full of biotech companies that may or may not bring a drug to market and may or may not become the apple … Full story available on Benzinga.com
   There's A Really Good Chance You Missed One Of The Year's Best ETFs  2019/12/09 12:25:13 Benzinga
Investors have been piling into exchange traded funds again this year, mostly pure beta, core equity and fixed income funds. The list of the top asset-gathering ETFs reads like rundown of the usual suspects . There's nothing wrong with that, but as investors flock to broad market equity and aggregate bond funds to keep up with the Joneses, they miss out on tactical opportunities like the Virtus LifeSci Biotech Clinical Trials ETF (NYSE: BBC ). BBC, which turns five years old this week, is up 41.14% year to date, thanks in large part to a fourth-quarter gain of 25.7%. Why It's Important BBC tracks the LifeSci Biotechnology Clinical Trials Index, a basket of early-stage biotechnology companies. Said another way, BBC is chock full of biotech companies that may or may not bring a drug to market and may or may not become the apple … Full story available on Benzinga.com
   There's A Really Good Chance You Missed One Of The Year's Best ETFs  2019/12/09 12:25:13 Benzinga
Investors have been piling into exchange traded funds again this year, mostly pure beta, core equity and fixed income funds. The list of the top asset-gathering ETFs reads like rundown of the usual suspects . There's nothing wrong with that, but as investors flock to broad market equity and aggregate bond funds to keep up with the Joneses, they miss out on tactical opportunities like the Virtus LifeSci Biotech Clinical Trials ETF (NYSE: BBC ). BBC, which turns five years old this week, is up 41.14% year to date, thanks in large part to a fourth-quarter gain of 25.7%. Why It's Important BBC tracks the LifeSci Biotechnology Clinical Trials Index, a basket of early-stage biotechnology companies. Said another way, BBC is chock full of biotech companies that may or may not bring a drug to market and may or may not become the apple … Full story available on Benzinga.com

 関連キーワード  (― 米国株 BBC Virtus LifeSci Biotech Clinical Trials ETF)

 twitter  (公式ツイッターやCEOツイッターなど)